Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 27 for “"HBV DNA"”.
-
Comparison of Serum HBV DNA Levels between Lamivudine Induced HBeAg Seroconversion and Spontaneous Seroconversion
… B. The aim of this study was to compare serum HBV DNA levels at the time of HBeAg seroconversion between these two groups. METHODS: We retrospectively analyzed 37 patients with chronic hepatitis B. Among them, 14 were seroconverted during lamivudine therapy and 13 were not seroconverted during …
-
Association of HBV DNA and ALT Level with YMDD motif Mutation Type in Lamivudine Resistance for Chronic Hepatitis B
… of lamivudine resistant hepatitis B virus(HBV), with point mutation in the YMDD motif of DNA polymerase gene, has been reported in chronic hepatitis B patients with lamivudine treatment. The aim of this study was to investigate the distribution patterns and clinical aspects of lamivudine …
-
Expression and Functional Analysis of Hepatitis B Virus DNA Polymerase
PART I: Expression of chimeric DNA polymerase of human and duck hepatitis B virus Hepatitis B Virus (HBV) DNA polymerase is a multifunctional protein with four domains, terminal protein (TP), spacer, reverse transcriptase (RT), and RNaseH. Since HBV DNA polymerase is very unstable and rapidly …
-
Initial Stages of Hepatitis B Virus Replication
PART 1 Intracellular Trafficking of HBV Core Particle in Various Stage of DNA Replication Inside of hepatitis B virus (HBV) core particle, pgRNA is reverse transcribed by HBV DNA polymerase into minus-strand DNA and pregenomic RNA (pgRNA) is degraded concomitantly by RNase H activity of DNA …
-
Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
… at least three times undetectable level of HBV DNA leave 6months space in 45 patients. (25 with entecavir, 14 with lamivudine, 6 with adefovir.) All patients had followed up at least 1 year after stopping NUC therapy. Serum ALT, AST and HBV DNA levels were measured every 3 months. Clinical …
-
Clinical Course of Partial Virological Responders
… of ETV therapy, respectively (P=0.008). Low HBV DNA level at 12 months (P<0.001) and absence of a LAM treatment history (P =0.031) were significant associated factors for VR. In VR prediction at 36 months of ETV therapy in NUC- naïve patients, HBV DNA level <95 IU/ml at 12 months showed a …
-
Analysis of Treatment Effect of Lamivudine, Adefovir Add-on Therapy in Patients with Lamivudine Resistant Chronic B-viral Hepatitis
… therapy. Liver function test, hepatitis B virus (HBV) DNA and HBeAg/HBeAb were assessed every 3 months. ADV associated (rtA181T/V and rtN236T) mutations were looked for at intervals in all HBV DNA-positive serum samples, yearly Results: Cumulative ratio of undetectable HBV DNA level (<50 copies/mL …
-
Critical C-termical Amino Acids of Hepatitis B Virus Core Proteins for HBV Replication
B형 간염 바이러스는 Hepadnaviridae Family로써, 크기가 3.2kb인 partieally duplex DNA genome을 가지고 있으며, 4개의 open reading frame (ORF)으로부터 core protein, surface protein, DNA polymerase, X protein을 발현한다. HBV core protein은 183개 또는 185개의 amino acid로 구성되어있는 22kDa의 단백질이며, HBV core protein은 pgRNA 의 encapsidation 및 DNA 합성에 …
-
C-terminus of Hepatitis B virus RNase H Domain is Important for HBV replication
Hepatitis B Virus (HBV) DNA polymerase (P) protein consisting of terminal protein (TP), spacer, reverse transcriptase (RT), and RNase H, plays critical roles in viral assembly and replication. RNase H domain is required for HBV DNA replication, however critical motif or amino acid residues in the …
-
Cytokine gene transfer by adenoviral vectors as a novel therapeutic option for hepatitis B virus infection
Hepatitis B virus (HBV) is a hepatotropic, non-cytopathic DNA virus that causes acute and chronic necroinflammatory liver disease and hepatocellular carcinoma. It has been shown that HBV DNA replication is suppressed by interferon (IFN) a/b, IFNg and other cytokines. The aim of my thesis was to …
-
Emergence of Adefovir-resistant Mutants after Reversion to YMDD Wild-type in Lamivudine-resistant Patients
The levels of hepatitis B virus (HBV) DNA have been reported to be a predominant viral risk factor associated with increased rates of cirrhosis and hepatocellular carcinoma. Lamivudine (LAM) is the first nucleoside analogue approved for the treatment of Chronic hepatitis B (CHB) with good potency, …
-
Analysis of Treatment Effect of Lamivudine plus Adefovir Add-on Therapy in Patients with Lamivudine Resistant Chronic B-viral Hepatitis
… 93명을 대상으로 후향적 방법을 사용하여 진행하였다. 결과: 6개월, 1년, 2년 누적 HBV DNA 음전율은 HBeAg 양성인 군에서는 각각 15.7%, 27.1%, 45.4%로 나타났고 HBeAg 음성인 군에서는34.8%, 39.1%, 52.6%로 나타났다. HBeAg의 혈청학적 누적 음전율은 6개월, 1년, 2년 동안 10.0%, 17.1%, 20.0%로 조사되었다. 바이러스 돌파 현상은 전체 추적 관찰 기간 동안 2.1%에서 관찰되었다. 결론: 라미부딘 내성 B형 간염 환자에게 아데포비어를 추가하여 치료하였을 때 항 …
-
Functional Role of Hepatitis B Virus Core Protein in Viral Replication
… carboxyl-terminal nucleic acid binding domain of HBV core protein for hepatitis B virus (HBV) replication, chimeric HBV core proteins were generated by substituting varying lengths of the carboxyl-terminus of duck hepatitis B virus (DHBV) core protein for the corresponding regions of HBV core …
-
Entecavir Therapy for Patients with Hepatitis B Virus-Related Decompensated Cirrhosis
목적: 엔테카비어는 HBV에 강력한 항바이러스 효과가 있으며 내성이 드물게 발생한다. 비대상성 간경변증 환자에서 엔테카비어의 장기 치료 효과에 대한 연구 결과는 많지 않다. 이에 저자들은 B형 간염 바이러스에 의한 비대상성 간경변환자를 대상으로 엔테카비어 치료 효과와 엔테카비어 효과를 예측할 수 있는 인자를 알아보고자 하였다. 대상 및 방법: 2006년 11월부터 2011년 1월까지 아주대학교 병원에 내원한 만성 B형 간염으로 인한 비대상성 간경변 환자 중 6개월이상 엔테카비어 치료를 받은 45명을 후향적으로 조사하였다. 대상 …
-
Changes in the Oral Cavity and Common Diseases /// Промени в оралната среда и общи заболявания
… in controls. Unstimulated saliva contains viral HBV DNA, but not HCV RNA. Immunity after vaccination for hepatitis B have only 40 percent of children between 6 and 15 years of age and below 30% of dental technicians. Tracking the level of calprotectin in saliva reveals a decrease in values after …
-
Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine resistant chronic hepatitis B patients
… and adefovir resistance in lamivudine resistant HBV infected patients. MATERIALS AND METHODS: Between March 2004 and December 2006, 76 patients with lamivudine-resistance who had received adefovir for more than 12 months were included. Assay of adefovir-resistant mutant was performed at 6 months …
-
Efficacy of Entecavir in Patients with Hepatitis B virus-Related Decompensated Liver Cirrhosis
… 후향적으로 조사하였다. 대상 환자는 12개월 이상 HBsAg과 B형 간염 바이러스(HBV) DNA양성이었고, Child-Pugh 점수가 8점 이상 이었다. HBeAg은 13명에서 양성이었고, HBV DNA의 중간 값은 7.2 x 106 IU/ml 였다. 엔테카비어 투여 후 Child-Pugh점수가 2점 이상 감소한 경우를 임상적 호전으로 정의하였다. HBV DNA 및 혈액검사는 3개월 간격으로 측정하였으며, HBV DNA는 real time PCR로 측정하였다. 결과: HBV DNA는 엔터카비어 투여 6개월째 76.5%, …
-
HBV genotypes at the Groote Schuur Hospital Liver Clinic, Cape Town : genotype and subgenotype prevalence and the influence of ethnicity on treatment outcomes during long term clinical follow-up of patience with chronic HBV infection.
In the developing world, hepatitis B virus (HBV) is an important cause of acute and chronic liver disease. Two billion people worldwide are infected with the virus and an estimated 350 million who have failed to clear the virus have chronic infection. In Africa, HBV is endemic with 98% of the …
-
Phenotypic characterization of a clinical HBV/G isolate relative to a co-infecting HBV/A strain and HBV/A/G recombinant strains
Hepatitis B virus genotype G (HBV/G) is a unique genotype of HBV which contains a 36-nucleotide insertion in the Core gene as well as 2 mutations that lead to stop codons in the Pre-Core coding region. Chronic infection with HBV/G is not known to occur without a co-infecting HBV genotype, …
Page 1 of 2